WCLC 2025 - Posters & ePosters-EP.14.01 Chemotherapy Plus Bevacizumab and Immunotherapy Prolonged the Survival of Unresectable Malignant Mesothelioma Patients in First-Line

EP.14.01 Chemotherapy Plus Bevacizumab and Immunotherapy Prolonged the Survival of Unresectable Malignant Mesothelioma Patients in First-Line

Back to course

Pdf Summary

This retrospective real-world study evaluated the efficacy and safety of first-line treatment regimens in 128 patients with unresectable malignant pleural mesothelioma (MPM). Patients received either chemotherapy alone (group A), chemotherapy plus bevacizumab (group B), or chemotherapy combined with both anti-angiogenic therapy and immunotherapy (group C). Baseline characteristics such as age, ECOG status, stage, gender, and histology were comparable across groups.<br /><br />Results showed that progression-free survival (PFS) was longer in groups B and C compared to chemotherapy alone: median PFS was 8.6 months in group A, 9.7 months in group B, and 16.4 months in group C, though the difference among groups did not reach conventional statistical significance (p=0.101). Overall survival (OS) median times were 24.9 months for group A, 26.4 months for group B, and not reached for group C (p=0.326). However, multivariate Cox regression analysis demonstrated that the four-drug regimen (chemotherapy+anti-angiogenic+immunotherapy) significantly prolonged both PFS (HR 0.29, p=0.007) and OS (HR 0.27, p=0.029) compared to chemotherapy alone. No significant difference was observed in grade 3 adverse event rates across groups, indicating tolerable toxicity.<br /><br />These findings align with the recent ETOP 13-18 BEAT-meso phase III trial, where the addition of bevacizumab and atezolizumab to chemotherapy improved PFS but not OS. The data suggest that combining chemotherapy with angiogenesis inhibitors and immunotherapy may enhance survival outcomes in unresectable MPM patients without increased severe toxicity. Further prospective studies are warranted to confirm these benefits.<br /><br />The study was funded by the Chinese Society of Clinical Oncology and highlights an emerging therapeutic strategy for first-line management of unresectable MPM.

Asset Subtitle

Yuyan Wang

Meta Tag

Speaker Yuyan Wang

Topic Mesothelioma, Thymoma, and Other Thoracic Tumors

Keywords

malignant pleural mesothelioma

first-line treatment

chemotherapy

bevacizumab

anti-angiogenic therapy

immunotherapy

progression-free survival

overall survival

retrospective study

treatment efficacy